Veru granted expedited provisional registration regulatory pathway for sabizabulin treatment in hospitalized covid-19 patients by australia's therapeutic goods administration

Miami, aug. 22, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral and ards-related diseases and for the management of breast and prostate cancers, today announced that australia's therapeutic goods administration (tga) has determined that sabizabulin treatment in hospitalized covid-19 patients at high risk for acute respiratory distress syndrome (ards) qualifies for an expedited, provisional registration regulatory pathway.
VERU Ratings Summary
VERU Quant Ranking